2.61
Bioxcel Therapeutics Inc stock is traded at $2.61, with a volume of 1.08M.
It is up +2.76% in the last 24 hours and down -16.08% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$2.54
Open:
$2.57
24h Volume:
1.08M
Relative Volume:
0.12
Market Cap:
$41.78M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.4251
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
+2.35%
1M Performance:
-16.08%
6M Performance:
+44.20%
1Y Performance:
+395.73%
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BTAI
Bioxcel Therapeutics Inc
|
2.61 | 49.90M | 1.38M | -179.05M | -155.03M | -6.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-21-24 | Downgrade | UBS | Buy → Neutral |
Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
Jul-07-22 | Initiated | Mizuho | Buy |
Apr-06-22 | Reiterated | BofA Securities | Buy |
Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
Apr-09-21 | Initiated | Berenberg | Buy |
Feb-01-21 | Initiated | UBS | Buy |
Oct-30-20 | Initiated | Goldman | Buy |
Sep-02-20 | Initiated | Jefferies | Buy |
Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
Jun-04-20 | Initiated | Guggenheim | Buy |
Apr-01-20 | Initiated | BofA/Merrill | Buy |
Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Why BioXcel Therapeutics Inc. stock could see breakout soonInsider Buying & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-13 07:29:55 - newser.com
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October - GlobeNewswire
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation - Stock Titan
Strategies to average down on BioXcel Therapeutics Inc.Trade Analysis Summary & Smart Money Movement Tracker - newser.com
BioXcel Therapeutics announces pricing of $7M public offering - MSN
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN
BioXcel Therapeutics Inc. stock outlook for YEARShare Buyback & Low Drawdown Momentum Ideas - newser.com
How BioXcel Therapeutics Inc. (BX20) stock reacts to stronger dollarWeekly Stock Analysis & Low Risk Profit Maximizing Plans - newser.com
BioXcel Therapeutics Receives Positive FDA Feedback - MSN
Sentiment analysis tools applied to BioXcel Therapeutics Inc.Weekly Investment Report & Precise Swing Trade Entry Alerts - newser.com
Is BioXcel Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Movers & High Conviction Trade Alerts - newser.com
BioXcel Therapeutics Inc. stock daily chart insights2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com
What drives BioXcel Therapeutics Inc BX20 stock pricePrice Action Analysis & Double Or Triple Wealth - earlytimes.in
How BioXcel Therapeutics Inc. (BX20) stock responds to bond marketJuly 2025 Outlook & Growth Focused Entry Reports - newser.com
Will BioXcel Therapeutics Inc. stock recover faster than peersQuarterly Portfolio Report & Weekly Watchlist for Hot Stocks - newser.com
Is BioXcel Therapeutics Inc. stock reversal real or fakeEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com
BioXcel Therapeutics Inc. stock chart pattern explained2025 Market Sentiment & Community Driven Trade Alerts - newser.com
BioXcel Investors Advance Suit Over FDA Study Compliance Issues - Bloomberg Law News
What analysts say about BioXcel Therapeutics Inc stockMean Reversion Trades & Market Monitoring and Alerts - earlytimes.in
BioXcel Therapeutics Inc Stock Analysis and ForecastSell Signals and Alerts & Control Your Emotions With Discipline Tools - earlytimes.in
User - FinancialContent
BioXcel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Volume spikes in BioXcel Therapeutics Inc. stock – what they meanJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Real time scanner hits for BioXcel Therapeutics Inc. explained2025 Volatility Report & Weekly High Return Opportunities - newser.com
Fundamentals Check: Is BioXcel Therapeutics Inc benefiting from interest rate changesWeekly Trade Report & Technical Analysis for Trade Confirmation - خودرو بانک
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 166.4% in August - MarketBeat
ETF Watch: How cyclical is BioXcel Therapeutics Incs revenue streamAnalyst Upgrade & Risk Controlled Stock Pick Alerts - خودرو بانک
Aug Reactions: How cyclical is BioXcel Therapeutics Incs revenue streamJuly 2025 Trends & Reliable Price Breakout Alerts - khodrobank.com
BioXcel Therapeutics regains Nasdaq compliance after MVLS issue By Investing.com - Investing.com South Africa
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioxcel Therapeutics Inc Stock (BTAI) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):